MedicaidPrior AuthMedium impact
Beovu® (brolucizumab) (New)
Humana·OH · Ophthalmology, Endocrinology·Medicaid
Effective date
Oct 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has established a new prior authorization policy for Beovu (brolucizumab) intravitreal injections, effective October 1, 2025. Prior authorization is required for both wet AMD and diabetic macular edema treatments, with specific criteria requiring contraindication, intolerance, or lack of response to bevacizumab first.
Action Required
Before October 1, 2025: Clinical staff must obtain prior authorization for all Beovu (brolucizumab) intravitreal injections for Humana Medicaid Ohio members. Update prior authorization tracking system to include Beovu for wet AMD and diabetic macular edema. Ensure documentation shows contraindication, intolerance, or failed response to bevacizumab before requesting authorization. Claims will be denied without prior authorization.